Quantcast

Latest Prostate cancer Stories

2014-07-31 23:20:55

According to relationship specialist Dr. Daniel Watter with Morris Psychological Group, most men treated for prostate cancer suffer a disruption in either libido or sexual function – or both – that may be temporary or may be long-lasting. It's important for the couple to communicate openly with each other and with his medical team both before treatment to be prepared for possible side effects and after treatment to adjust to the physical and emotional impact on their relationship....

2014-07-29 04:22:06

OXFORD, England, July 29, 2014 /PRNewswire/ -- Glide Pharmaceutical Technologies Ltd (Glide Pharma) today announced that it has taken an exclusive worldwide licence to an innovative prostate cancer diagnostic technology from FScan Ltd, a Durham University spin-out company. Under the terms of the agreement, Glide Pharma will pay an upfront fee, development and commercial milestone payments, and royalties on future product sales. Glide Pharma has also taken an option for...

2014-07-29 04:22:01

ROCKLAND, Massachusetts, July 29, 2014 /PRNewswire/ -- - First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC) - mMCC is a rare and aggressive skin cancer lacking effective treatments - MSB0010718C is also currently being explored in a seven cohort Phase I clinical trial for the treatment of solid...

2014-07-28 23:01:59

Individuals diagnosed with a covered Cancer on or prior to October 12, 2012 are included in the October 12, 2014 deadline. Port Washington, NY (PRWEB) July 28, 2014 Parker Waichman LLP, a personal injury law firm that has spent many years fighting to ensure that the heroes of 9/11 are never forgotten, comments that the September 11th Victims Compensation Fund (VCF) has announced an important deadline. According to a VCF message dated July 3, 2014, individuals who were diagnosed with a...

2014-07-28 23:01:12

Discovery Accepted into NCI Drug Development Program for Clinical Trials Philadelphia, PA (PRWEB) July 28, 2014 An estimated 68,000 women and men in the U.S. die each year from metastatic breast and prostate cancers – an aggressive form of the disease that occurs when the cancer has spread to other parts of the body, such as the lungs, liver, bones, or brain. Now researchers at Drexel University College of Medicine have developed a compound directed at a target they identified that...

2014-07-25 08:25:15

Phase I studies start in 2015 NEW HAVEN, Conn., July 25, 2014 /PRNewswire/ -- Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd. (ASX; NRT: NASDAQ; NVGN), today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil(TM). CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound...

2014-07-23 23:18:30

Transparency Market Research published a new report "Circulating Tumor Cells (CTCs) Prognostic Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" to its report store. Browse the full report: http://www.transparencymarketresearch.com/ctcs-prognostic-technologies-market.html Albany, New York (PRWEB) July 22, 2014 According to a new market report published by Transparency Market Research “Circulating Circulating Tumor Cells (CTCs)...

2014-07-22 08:32:06

New product offers treatment to significant unmet medical need in supportive cancer care DALLAS and NEW YORK, July 22, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard(TM), its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of...

2014-07-22 08:31:31

"These positive results enable management to remain optimistic about our ambitious G-202 clinical development program"- Dr. Craig Dionne, CEO SAN ANTONIO, July 22, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and...

2014-07-17 23:08:44

Dr. Mark Soloway, who has been appointed Chief of Urologic Oncology at Memorial Cancer Institute, will lead a new division focused on the care of bladder, prostate and kidney cancers, while also establishing a research program. Hollywood, Fla. (PRWEB) July 17, 2014 Mark Soloway, MD, an internationally recognized leader in urologic oncology, has joined the Memorial Cancer Institute and the Memorial Physician Group. Dr. Soloway, who has been appointed Chief of Urologic Oncology, will lead a...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related